Biophytis S.A. BPTSY

BPTSY Company Overview

Biophytis S.A. is a clinical-stage biotechnology company focused on the development of therapeutic candidates for age-related diseases, particularly conditions associated with muscle degeneration and respiratory failure. The company operates within the biotechnology and pharmaceutical research and development industries, with an emphasis on small-molecule drug candidates targeting biological pathways involved in muscle function and inflammation.

The company’s primary value driver is its lead drug candidate Sarconeos (BIO101), which has been investigated for indications including sarcopenia, respiratory complications, and severe COVID‑19–related respiratory failure. Biophytis primarily serves healthcare systems, clinicians, and aging patient populations through late-stage clinical development rather than commercialized products. Founded in France in the mid‑2000s, the company evolved from academic research into a publicly listed biotech, expanding its clinical focus and accessing international capital markets through listings in Europe and the United States.